![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Phase 2 Study of Pegylated Interferon Lambda for HCV: Safety, Viral Response, and Impact of Host Genotype Through Week 12
|
|
|
Reported by Jules Levin
21st APASL Conference, Bangkok, Thailand, February 17-20, 2011
Rodriguez-Torres M,1 Lawitz E,2 Ghalib RH,3 Sussman NL,4 Anderson F,5 Everson GT,6 Jacobson IM,7 Lopez-Talavera JC,8 Horga M-A,8 Hillson JL,9 Gray TE,9 Fontana DJ,9 Ramos EL,9 Muir AJ10 1Fundacion de Investigacion de Diego, Santurce, Puerto Rico, USA; 2Alamo Medical Research, San Antonio, TX, USA; 3North Texas Research Institute, Dallas, TX, USA; 4Baylor College of Medicine, Houston, TX, USA; 5Liver and Intestinal Research Centre, Vancouver, BC, Canada; 6University of Colorado Hospital, Aurora, CO, USA; 7Weill Cornell Medical College, New York, NY, USA; 8Bristol-Myers Squibb, Wallingford, CT, USA; 9ZymoGenetics, Inc., Seattle, WA, USA; 10Duke University Medical Center, Durham, NC, USA
![apasl1.gif](../images/022411/022411-1/apasl1.gif)
![apasl2.gif](../images/022411/022411-1/apasl2.gif)
![apasl3.gif](../images/022411/022411-1/apasl3.gif)
![apasl4.gif](../images/022411/022411-1/apasl4.gif)
![apasl5.gif](../images/022411/022411-1/apasl5.gif)
![apasl6.gif](../images/022411/022411-1/apasl6.gif)
![apasl7.gif](../images/022411/022411-1/apasl7.gif)
![apasl8.gif](../images/022411/022411-1/apasl8.gif)
![apasl9.gif](../images/022411/022411-1/apasl9.gif)
![apasl10.gif](../images/022411/022411-1/apasl10.gif)
![apasl11.gif](../images/022411/022411-1/apasl11.gif)
![apasl12.gif](../images/022411/022411-1/apasl12.gif)
![apasl13.gif](../images/022411/022411-1/apasl13.gif)
![apasl14.gif](../images/022411/022411-1/apasl14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|